<DOC>
	<DOCNO>NCT01348607</DOCNO>
	<brief_summary>RATIONALE : Methylphenidate hydrochloride modafinil may help reduce daytime sleepiness improve quality life patient excessive daytime sleepiness cancer therapy . It yet know whether methylphenidate hydrochloride modafinil effective placebo reduce daytime sleepiness patient . PURPOSE : This randomized phase II trial study methylphenidate hydrochloride modafinil see well work compare placebo treat young patient excessive daytime sleepiness cancer therapy .</brief_summary>
	<brief_title>Methylphenidate HCl Modafinil Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy methylphenidate hydrochloride modafinil placebo pediatric patient excessive daytime sleepiness follow cancer therapy . Secondary - Compare efficacy half dose methylphenidate hydrochloride modafinil placebo patient . - Assess effect regimens daytime sleepiness measure Pediatric Daytime Sleepiness Scale Cleveland Adolescent Sleepiness Questionnaire . - Assess effect somnolence symptom fatigue measure PedsQL Multidimensional Fatigue Scale . - Assess effect somnolence symptom quality life measure PedsQL Quality Life Inventory 4.0 . - Determine incidence side effect associate regimen . - Determine prevalence sleep complaint measure Pediatric Sleep Questionnaire . ( Exploratory ) OUTLINE : This multicenter study . Patients stratify accord age ( 8-10 year v 11-12 year v 13-17 year v 18-25 year ) . Patients randomize 1 3 treatment arm . - Arm I : Patients receive oral methylphenidate hydrochloride extended-release daily 7-42 day absence unacceptable toxicity . - Arm II : Patients receive oral modafinil daily 7-42 day absence unacceptable toxicity . - Arm III : Patients receive oral placebo daily 7-42 day absence unacceptable toxicity . Patients parent complete age-specific sleep quality-of-life questionnaire baseline completion treatment . Patients parent complete daily sleep diary study collect information date , type day ( school , weekend , vacation ) , hour sleep , anytime actigraph remove day , time child go bed , time child get bed morning . Patients also instruct wear actigraph non-dominant wrist 1 week start treatment first last week treatment ( 3 week total ) ass sleep-wake pattern .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>INCLUSION CRITERIA : Patient family must agree return clinic 8 time within 2 month Children â‰¥ 8 &lt; 18 year age time study entry previously treat : hypothalamic tumor midline brain tumor tumor involve one thalamus craniopharyngioma diagnosis hydrocephalus secondary brain tumor treatment brain tumor require placement permanent shunt . Off cancer treatment least six month Proficient English Able swallow capsule Experiencing symptom excessive daytime sleepiness ( EDS ) least three month prior study entry result inadequate sleep hygiene know medical disorder . Negative pregnancy test EXCLUSION CRITERIA : Patients treat doxorubicin high dose cyclophosphamide History clinically significant drug sensitivity methylphenidate , modafinil , armodafinil component Known cardiac disorder include arrhythmia , hypertension require treatment structural heart disease Have take methylphenidate modafinil within last 14 day Current/concurrent use antihistamine , benzodiazepine , anticonvulsant alcohol Clinical diagnosis major depression , subclinical depression , anxiety disorder History psychosis mania Patients suicidal ideation Diagnosis anemia , untreated hypothyroidism , mononucleosis narcolepsy History substance abuse Pregnant breast feed A total dietary intake 500 mg caffeine per day ( e.g. , approximately ten 330 mL can soft drink , five cup coffee tea , 750 g chocolate per day ) .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>sleep disorder</keyword>
	<keyword>fatigue</keyword>
	<keyword>childhood craniopharyngioma</keyword>
</DOC>